Similar articles

• XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.

  Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE. Koehler M, et al. Bone Marrow Transplant. 1994 May;13(5):571-5. Bone Marrow Transplant. 1994. PMID: 7519937
• Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.

  Weisdorf D, Filipovich A, McGlave P, Ramsay N, Kersey J, Miller W, Blazar B. Weisdorf D, et al. Bone Marrow Transplant. 1993 Nov;12(5):531-6. Bone Marrow Transplant. 1993. PMID: 8298565 Clinical Trial.
• Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.

  Przepiorka D, Chan KW, Champlin RE, Culbert SJ, Petropoulos D, Ippoliti C, Khouri I, Huh YO, Vreisendorp H, Deisseroth AB, et al. Przepiorka D, et al. Bone Marrow Transplant. 1995 Dec;16(6):737-41. Bone Marrow Transplant. 1995. PMID: 8750262
• Perspectives in the prevention and treatment of acute graft versus host disease.

  Herve P. Herve P. Bone Marrow Transplant. 1991;7 Suppl 2:117-9. Bone Marrow Transplant. 1991. PMID: 1715225 Review. No abstract available.
• Graft versus host disease prophylaxis today.

  Martelli MF, Aversa F. Martelli MF, et al. Bone Marrow Transplant. 1991;7 Suppl 2:112-6. Bone Marrow Transplant. 1991. PMID: 1908726 Review. No abstract available.